IBM Micromedex NeoFax Pediatrics

Five reasons to use IBM Micromedex NeoFax and Pediatrics

Ensures the highest levels of drug safety

Infants and children are an especially vulnerable patient population, particularly regarding medication safety. IBM Micromedex NeoFax and Pediatrics addresses the unique needs of these patients to enable clinicians to make safer, more informed decisions about their medications.

Delivers population-specific drug information

The monographs are focused specifically on neonatal or pediatric drug therapy. The content is evidence-based, fully referenced, off-label focused and designed to allow clinicians quick and reliable access to only the most population-specific information. The patient populations of both IBM Micromedex NeoFax and IBM Micromedex Pediatrics are available within the same interface, providing one source of relevant drug knowledge – from the most premature neonate, up to age 18.

Provides age- and indication-specific dosing calculators

The solution includes dosing calculators for every drug in the individual solutions. These age- and indication-specific calculators are prepopulated with evidence-based recommendations that address dose, concentration and administration. This powerful clinical decision support functionality provides clinicians with the dosage options for each patient quickly. It also provides warning messages for out-of-range values, working to significantly decrease the risk for dosing errors.

Enhances enteral nutrition support

The enteral formula database within IBM Micromedex NeoFax and Pediatrics is an additional resource to support the nutritional health and well-being of neonatal and pediatric patients. With important information about infant formula and human milk fortifiers, this feature allows for comparison of multiple products to facilitate selection of the most appropriate nutritional support product.

Provides peace of mind when it matters most

IBM Micromedex NeoFax and Pediatrics builds on the 30-plus-year reputation of Micromedex NeoFax as one of the leading neonatal drug information resources. The neonatal and pediatric content is created using the comprehensive editorial processes and clinical rigor of IBM Micromedex, providing evidence-based information based on the best available population-specific published literature.

How customers use it

Clinical evidence for neonatal and pediatric care
Problem
Limited published literature, clinical trials and FDA-approved drugs exist for neonatal and pediatric populations. Many of the drugs prescribed to children are used off-label, presenting a set of unique problems.
Solution
IBM Micromedex NeoFax and Pediatrics provides population-, age- and indication-specific drug monographs and dosage recommendations to inform safe and effective off-label medication use.
Emergency department pediatric readiness
Problem
30 million children will visit an emergency department a year (2). 90% will go to non-pediatric focused EDs (3). EDs need resources to inform care and to mitigate risk for medication errors and adverse drug events. See citations in Resources Section.
Solution
Having an evidence-based neonatal and pediatric focused drug information resource will provide peace of mind for physicians, nurses and pharmacists when a baby or child presents to the ED or inpatient setting requiring treatment.
Health plan and pharmacy benefit manager decision making
Problem
Medically complex children account for 20% of medical services and 80% of children’s health costs (4). Health Plans and PBMs need evidence to support prior authorization, drug coverage and care management for the group. Citations in Resource Section.
Solution
An evidence-based neonatal and pediatric drug information resource will provide clinically relevant content to support payment, Pharmacy and Therapeutics Committee, and care management decisions for neonatal and pediatric therapy.